Ambazone

Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.A selective inhibitor of JAK1 and JAK2.

Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.A selective inhibitor of JAK1 and JAK2.

Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.A selective inhibitor of JAK1 and JAK2.

Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.A selective inhibitor of JAK1 and JAK2.

Legal Information AnhydroBeads is a trademark of Sigma-Aldrich Co. LLC

Legal Information AnhydroBeads is a trademark of Sigma-Aldrich Co. LLC

Application Reagent for facile synthesis of poly(phenylcarbyne), a precursor to diamond-like carbon. Legal Information AnhydroBeads is a trademark of Sigma-Aldrich Co.

Application Reagent for facile synthesis of poly(phenylcarbyne), a precursor to diamond-like carbon. Legal Information AnhydroBeads is a trademark of Sigma-Aldrich Co.

Bebtelovimab (anti-Spike RBD).

Bebtelovimab (anti-Spike RBD).

Analysis Note Assay (GC, area%): &#8805 98.0 % (a/a) Density (d 20&#8199&#176C/ 4&#8199&#176C): 0.

BLZ945 is a tumor-associated macrophage targeting the treatment of glioblastoma multiforme, a most common type of aggresive brain cancer.